In BRAF-mutated metastatic melanoma and EGFR-mutated advanced non-small cell lung cancer (NSCLC), small molecule inhibitors targeting BRAF or EGFR, respectively, significantly increased the overall survival and have become the standard of care in these patients [20,21,22]. Here, BRAF is linked to metastatic melanoma.